analysis. E. p38 inhibitors are synergistic with AZD1208. OCI-M1, OCI-M2, U2932, K562, and TMD8 cells were treated with 2-fold dilutions of AZD1208, SB202190, SCIO-469, or the combination for 5 days. Viability was assessed by CellTiter-Blue and used to calculate combination indices. Self-self combination treatments were used as a baseline to determine significance (n=3). P-values were calculated using a one-way ANOVA and Dunnett's test. p ≤ 0.05 (*), p ≤ 0.01 (**), and p ≤ 0.0001 (****) F. Dual p38/PIM inhibition represses mTOR signaling. TMD8, U2932, and K562 cells were treated for 48 hours with 1 μM AZD1208, 20 μM SB202190, or the combination. Cell lysates were harvested and subjected to western blot analysis (n=2). G. PIM inhibitor resistant AML cell lines are sensitive to mTOR inhibition. OCI-M1, OCI-M2, MOLM16, and KG1a cells were treated with increasing concentrations of the mTOR inhibitor AZD8055 (x-axis). Viability was measured after 5 days using Cell-Titer-Blue (n=3) 
